Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Tisotumab Vedotin in Cervical Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Patients with extra-pelvic metastatic or recurrent cervical cancer including squamous cell, adenocarcinoma or adenosquamous histology who have experienced disease progressed on standard of care chemotherapy in combination with bevacizumab, if eligible.~* Measurable disease according to RECIST v1.1 as assessed by IRC.~* Age ≥ 18 years.~* Acceptable renal function~* Acceptable liver function~* Acceptable hematological status~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* A negative serum pregnancy test for patients of reproductive potential.~* All patients must provide a fresh or archival biopsy during screening.~* Following receipt of verbal and written information about the trial, patients must provide signed informed consent before any trial-related activity is carried out.~Exclusion Criteria~* Have received no more than 2 prior systemic treatment regimens for recurrent or metastatic cervical cancer.~* Known past or current coagulation defects leading to an increased risk of bleeding;~* Ongoing major bleeding~* Active ocular surface disease~* Known past or current malignancy other than the inclusion diagnosis.~* Peripheral neuropathy grade ≥ 2

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single arm (Type: EXPERIMENTAL): tisotumab vedotin (IV), 2.0 mg/kg, every 3 weeks (1Q3W)

Based on this trial design, predict the completion outcome and termination type (if applicable).